HCMC – Vietnam Vaccine Joint Stock Company (VNVC) has signed a contract to purchase a fully robotized vaccine production line from Syntegon, with installation scheduled for August 2027 and commercial operation targeted for the end of 2027.
The signing ceremony took place in Hanoi February 24.
Under the agreement, Syntegon will supply a high-tech vaccine production line manufactured in Germany. The system applies “No Touch Transfer” technology, enabling sterile material transfer without human contact. It uses robots and fully isolated isolator chambers, along with advanced process control solutions, to maximize automation in sterile areas.
The entire process, from packaging supply and filling to sealing and final packaging, will be carried out by robots and specialized automated procedures. The equipment will be designed and manufactured in Germany immediately after contract signing.
The production line is capable of manufacturing four common vaccine formats: liquid vials, lyophilized vials, prefilled syringes and injection pens. It operates at filling speeds of up to hundreds of vials or syringes per minute, with dosing accuracy ranging from 0.1 milliliters to 20 milliliters. For oxygen-sensitive products, the system integrates inert gas filling before sealing to ensure product stability and quality.
According to the Ministry of Health, Vietnam has made significant progress in expanding immunization coverage and preventing infectious diseases but requires additional vaccine and biological production facilities that meet global quality standards.
Once operational, the plant is expected to enable Vietnam to gradually master the vaccine value chain, from research and training to the production of next-generation vaccines at reasonable costs. The investment places the VNVC vaccine and biological manufacturing plant among the world’s 20 most technologically advanced facilities in its initial production phase.
The facility is positioned to meet stringent international quality standards, including EU-GMP, US-FDA and WHO-GMP requirements, in line with national policies and the Law on Disease Prevention recently passed by the National Assembly.
